Which is better, eltrombopag, eltrombopag or avatrombopag?

Eltrombopag, heltrombopag and avatrombopag are all drugs used to treat thrombocytopenia. They are all thrombopoietin receptor agonists (TPO-RA).

Eltrombopag and Hetrombopag have a hydrazide structure, which is easy to chelate with metal cations. Once a chelate is formed, the exposure of the drug in the blood will be significantly reduced, thus affecting the efficacy of the drug. The structure of avatrombopag does not contain hydrazide, but contains benzothiazole, which is not easy to chelate with metal cations, so its blood concentration and efficacy are more stable.

In terms of pharmacokinetics, the bioavailability of avatrombopag is as high as100%, which means that the drug after oral administration is fully absorbed without loss. Its half-life is 7-9 hours, indicating a long-lasting effect. In contrast, eltrombopag and heltrombopag have lower bioavailability and shorter half-lives, requiring more frequent dosing to maintain effective plasma concentrations.

Eltrombopag is mainly used to treat idiopathic thrombocytopenic purpura (ITP) and severe aplastic anemia (AA). It needs to be taken on an empty stomach, and it is necessary to avoid taking it with food or drugs containing polyvalent cations at the same time. Hetrombopag is suitable for adult patients with chronic primary immune thrombocytopenia (ITP) and severe aplastic anemia (SAA) who have poor response to glucocorticoids, immunoglobulins and other treatments. It also needs to be taken on an empty stomach. Avatrombopag is mainly used for adult patients with chronic liver disease-related thrombocytopenia who are scheduled to undergo elective diagnostic procedures or surgeries. The advantage is that it can be taken with food, providing patients with more convenience.

In terms of safety, eltrombopag may increase the risk of bleeding and should be contraindicated in patients with severe bleeding, thrombosis, or recent thrombotic events. In addition, it should also be contraindicated in patients with severe hepatic insufficiency. Avatrombopag is relatively safe, does not undergo UGT metabolism, and has no liver toxicity. Therefore, avatrombopag is the first choice for patients with liver dysfunction. Hatrombopag also has certain hepatotoxicity and requires special attention.

Regarding side effects, common side effects of eltrombopag include headache, diarrhea, nausea, etc.; heltrombopag may cause adverse reactions such as headache, fatigue, muscle pain, etc.; and the adverse reactions of avatrombopag mainly include fever, abdominal pain, nausea, etc. These side effects are manageable in most cases, but if severe discomfort occurs, seek medical attention immediately.

Taken together, eltrombopag, heltrombopag and avatrombopag are all effective thrombopoietin receptor agonists, but they differ in structure, pharmacokinetics, indications, usage and dosage, and safety. Avatrombopag has advantages in pharmacokinetics and convenience of administration, and is relatively safe. It is especially suitable for patients with hepatic insufficiency. However, the specific choice of drug depends on the patient's specific situation and the doctor's advice.

When choosing drugs, patients should fully understand the advantages and disadvantages of various drugs, fully communicate with their doctors, and make the best choice based on their own circumstances. At the same time, no matter which drug you choose, you need to use it strictly in accordance with the doctor's instructions, pay attention to the body's reaction, and adjust the treatment plan in a timely manner to ensure the safety and effectiveness of the treatment.